CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 21 enrolled
Drug / intervention
Probeneciddrug
Likely dose
Probenecid 500mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05082909
NCT05082909Phase 2Completed
CompareCT.gov

Addition of Probenecid to Penicillin-V Therapy: an Open Label, Cross-over Study in Healthy Volunteers

Imperial College London·interventional·Posted Oct 19, 2021·Updated Jan 30, 2025

In Brief

A Phase 2 clinical trial evaluating Probenecid for Infection, Bacterial. Completed, enrolled 21 participants across 1 site.

Detailed Summary

This study aims to build on previous work characterising the PK of penicillin-V to explore the potential impact of probenecid on PK-PD target attainment. Achievement of the aims of this study would provide data to support the design of experimental studies exploring the clinical impact of probenecid on treatment outcomes and also provide a rationale for exploration of probenecid's effects on a larger number of beta-lactam antibiotics. Hypothesis: Addition of probenecid to oral phenoxymethylpenicillin (penicillin-V) has a clinically relevant effect on pharmacokinetic-pharmacodynamic (PK-PD) target attainment.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsInfection, Bacterial
CountriesUnited Kingdom
Collaborators--

Timeline

Phase 2CompletedFinished
20222023202420252026
First PostedOct 19, 2021
Enrollment StartDec 21, 2021
Primary CompletionJul 7, 2022
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 4.7 years ago

Interventions

Probeneciddrug

Addition of 500mg QDS to oral penicillin.